They Just Don't Get...
Health Care: Drugs
Biocryst Pharmaceuticals (BCRX: NASDAQ)
$3.96 -0.11 | -2.70%
02/09/12 - 04:00 PM ET
127.21K / 182.50K
Vol / Avg. Vol:4.08 / 4.07
Open / Prev. Close:3.92 - 4.08
Today's Range:2.28 - 4.49
52 Wk Range:64.78%
Performance YTD:TheStreet Rating:
Portfolios with BCRX
- Portfolio NameUser Type
- ContributorUnder-$10 Setting Up To Tra...
- Usertech
- Userrio grande
- UserDebbie0913 Portfolio 1
- UserPART 7 JPMorgan 28th Annual...
- UserSolana Partners
- UserLatest 2009
- ContributorFast Money's 3 Buys & 4...
- User10 shots
- ContributorCramer's Healthcare Stock Buys
Latest BCRX Headlines from TheStreet
- 5 Under-$10 Stocks Set to Soar 12.29.11 | 06:12 pm
- Biocryst's Gout Drug Fails to Impress 10.05.11 | 11:10 am
- Dendreon's Blowup Spreads Across Biotech 08.04.11 | 10:08 am
- Biotech Stock Mailbag: Vivus 09.24.10 | 07:09 am
- BioCryst Tripped Up by Downgrade 09.23.10 | 04:09 pm
- Savient: Drug Approval or Another Delay? 09.10.10 | 08:09 am
- Biotech Calendar: Key Dates for September 09.01.10 | 07:09 am
- BioCryst Pharmaceuticals, Inc. Q1 2010 Earnings Call Transcript 04.28.10 | 06:04 pm
- Demand for BioCryst Flu Drug Still Low: BioBuzz 03.30.10 | 08:03 am
- 'Mad Money Lightning Round': Get in on FLIR Systems 01.14.10 | 07:01 pm
Press Releases for BCRX
- BioCryst To Announce Fourth Quarter And Full Year 2011 Financial Results On February 16, 2012 - Business Wire 02.06.12 | 06:02 am
- Nancy Hutson Appointed To BioCryst’s Board Of Directors - Business Wire 01.19.12 | 06:01 am
- BioCryst Announces Positive Results From Its Ongoing BCX4208 Phase 2B Study In Patients With Gout - Business Wire 01.08.12 | 05:01 pm
- BioCryst Pharmaceuticals Presents New BCX4208 Gout Data At The 2011 ACR/ARHP Annual Scientific Meeting - Business Wire 11.08.11 | 06:11 am
- BioCryst Pharmaceuticals Provides Corporate Update And Reports Third Quarter 2011 Financial Results - Business Wire 11.02.11 | 06:11 am
- BioCryst Pharmaceuticals Announces New BCX4208 Gout Data Has Been Accepted As A Late-Breaker Oral Presentation At The ACR/ARHP 2011 Annual Scientific Meeting - Business Wire 10.24.11 | 10:10 am
- BioCryst Pharmaceuticals To Announce Third Quarter 2011 Financial Results On November 2, 2011 - Business Wire 10.19.11 | 06:10 am
- BioCryst Announces Positive Top-Line Results From BCX4208 Phase 2B Gout Study In Patients Not Responding To Allopurinol Alone - Business Wire 10.05.11 | 06:10 am
- BioCryst To Present New Peramivir Data At The 51st Annual ICAAC Meeting - Business Wire 09.17.11 | 05:09 pm
- BioCryst To Present At Three Upcoming Investor Conferences - Business Wire 09.06.11 | 06:09 am
Partner Headlines for BCRX
- Oink Oink: Profit From The Return Of Swine Flu - Benzinga 01.12.12 | 01:01 pm
- Biotechs And Their Trials By Fire - Seeking Alpha 11.07.11 | 09:11 am
- Zacks #5 Rank Additions for Friday - Tale of the Tape - Zacks 11.04.11 | 09:11 am
- BioCryst Pharmaceuticals To Present New Peramivir Data at the 51st Annual ICAAC Meeting - Benzinga 09.17.11 | 06:09 pm
- A Bullish Speculative Options Bet and a Bearish One - Seeking Alpha 06.30.11 | 09:06 am
- 7 Speculative Healthcare Stocks to Rejuvenate Your Portfolio - Seeking Alpha 05.31.11 | 08:05 am
- UPDATE 1-BioCryst says influenza drug lowers virus concentration - Reuters 01.13.11 | 08:01 am
- Biotech and Pharma Stocks: High Volume Traders; (OTCBB: UVFT), (NASDAQ:AMGN), (OTCBB: GNTA), (NASDAQ:BCRX) - Benzinga 12.15.10 | 01:12 pm
- BioCryst Announces Positive Results of Potential Gout Treatment - Fox Business 09.16.10 | 02:09 pm
- UPDATE 1-BioCryst gout drug shows promise in mid-stage trial - Reuters 09.16.10 | 07:09 am
